Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

European Journal of Pharmacology

Volumn 536, Issue 1-2, 2006, Pages 182-191

  Nagasawa, Tatsuya ^a   Inada, Yoichi ^a   Nakano, Shigeru ^a   Tamura, Toru ^a   Takahashi, Tetsuaki ^a   Maruyama, Kazuyasu ^a   Yamazaki, Yoshinobu ^a   Kuroda, Junji ^a   Shibata, Nobuo ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

(Mouse); Bezafibrate; GW501516; Methionine choline deficient diet; NASH; PPAR

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACETYL COENZYME A ACETYLTRANSFERASE; ACYL COENZYME A OXIDASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ALANINE AMINOTRANSFERASE; BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE; CHEMOKINE; CYTOKINE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MESSENGER RNA; METHACHOLINE; METHIONINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; THIOBARBITURIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALCOHOLIC FATTY LIVER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FATTY ACID OXIDATION; FATTY LIVER; HISTOPATHOLOGY; LIPID LIVER LEVEL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN DEFICIENCY;

ACYL-COA OXIDASE; ALANINE TRANSAMINASE; ANIMALS; BEZAFIBRATE; CARNITINE O-PALMITOYLTRANSFERASE; CHOLESTEROL, HDL; CHOLINE; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID-BINDING PROTEINS; FATTY LIVER; GENE EXPRESSION; INTERLEUKIN-6; LIVER; MALE; METHIONINE; MICE; MICE, INBRED C57BL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR DELTA; RNA, MESSENGER; THIAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 33645891166     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.028     Document Type: Article

References (40)

1. Agrawal S., and Bonkovsky H.L. Management of nonalcoholic steatohepatitis: an analytic review. J. Clin. Gastroenterol. 35 (2002) 253-261
2. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
3. Blüher M., Fasshauer M., Kralisch S., Schon M.R., Krohn K., and Paschke R. Regulation of adiponectin receptor R1 and R2 gene expression in adipocytes of C57BL/6 mice. Biochem. Biophys. Res. Commun. 329 (2005) 1127-1132
4. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., and Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96 (2001) 519-525
5. Czaja M.J. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 40 (2004) 19-22
6. Day C.P., and James O.F.W. Steatohepatitis: a tale of two ''hits''?. Gastroenterology 114 (1998) 842-845
7. Folch J., Lees M., and Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
8. George J., Pera N., Phung N., Leclercq I.A., Hou J.Y., and Farrell G.C. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39 (2003) 756-764
9. Green R.M. NASH-Hepatic metabolism and not simply the metabolic syndrome. Hepatology 38 (2003) 14-17
10. Gressner A.M. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J. Hepatol. 22 2 Suppl. (1995) 28-36
11. Inoue I., Takahashi K., Katayama S., Harada Y., Negishi K., Itabashi A., and Ishii J. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats. Metabolism 44 (1995) 1626-1630
12. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., Matsunaga T., Hayashi K., Awata T., Komoda T., and Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290 (2002) 131-139
13. Ip E., Farrell G., Robertson G., Hall P., Kirsch R., and Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38 (2003) 123-132
14. Ip E., Farrell G., Hall P., Robertson G., and Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004) 1286-1296
15. Jansen P.L. Non-alcoholic steatohepatitis. Eur. J. Med. 16 (2004) 1079-1085
16. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
17. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., and Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
18. Kramer D.K., Al-Khalili L., Perrini S., Skogsberg J., Wretenberg P., Kannisto K., Wallberg-Henriksson H., Ehrenborg E., Zierath J.R., and Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes 54 (2005) 1157-1163
19. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
20. Loetscher P., Seitz M., Clark-Lewis I., Baggiolini M., and Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J. 8 (1994) 1055-1060
21. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., Romanelli R.G., Laffi G., and Gentilini P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 152 (1998) 423-430
22. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Hepatology 116 (1999) 1413-1419
23. Oneta C.M., and Dufour J.F. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med. Wkly. 132 (2002) 493-505
24. Rao M.S., and Reddy J.K. Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver Dis. 21 (2001) 43-55
25. Saibara T., Onishi S., Ogawa Y., Yoshida S., and Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353 (1999) 1802
26. Sato M., Suzuki S., and Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 28 (2003) 105-112
27. Senoo H. Structure and function of hepatic stellate cells. Med. Electron Microsc. 37 (2004) 3-15
28. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
29. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15924-15929
30. Tanaka T., Masuzaki H., Ebiharal K., Ogawa Y., Yasue S., Yukioka H., Chusho H., Miyanagal F., Miyazawa T., Fujimoto M., Kusakabe T., Kobayashi N., Hayashi T., Hosoda K., and Nakao K. Transgenic expression of mutant peroxisome proliferator-activated receptor (PPAR) γ in liver precipitates fasting-induced hepatic steatosis but protects against high fat diet-induced hepatic steatosis in mice. Metabolism 54 (2005) 1490-1498
31. Tenenbaum A., Motro M., Fisman E.Z., Schwammenthal E., Adler Y., Goldenberg I., Leor J., Boyko V., Mandelzweig L., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Circulation 109 (2004) 2197-2202
32. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Arch. Intern. Med. 65 (2005) 1154-1160
33. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102 (2000) 21-27
34. Trogan E., Choudhury R.P., Dansky H.M., Rong J.X., Breslow J.L., and Edward A. Fisher laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2234-2239
35. Weltman M.D., Farrell G.C., and Liddle C. Increased hepatocyte CYP2E1 expression in a rat model of hepatic steatosis with inflammation. Gastroenterology 111 (1996) 1645-1653
36. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., and Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27 (1998) 28-133
37. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
38. Wolfrum C., Ellinghaus P., Fobker M., Seedorf U., Assmann G., Borchers T., and Spener F. Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J. Lipid Res. 40 (1999) 708-714
39. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
40. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno NH., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769